The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a significant substantial